Abstract:The primary focus of bisphosphonate medications is on targeting human farnesyl pyrophosphate synthase (hFPPS), an essential regulator of mammalian isoprenoids. Yet, these drugs encounter limitations due to their restricted "druglike" properties and their effectiveness primarily in treating skeletal disorders. In this study, we synthesized novel non-bisphosphonate compounds, using 4,4'-(ethane-1,2-diylbis(oxy))bis(3-methoxybenzaldehyde) ( 1 ) as a starting compound, with the aim of targeting hFPPS through a mixed binding approach. Among the various compounds tested, compounds 4a and 4b exhibited significant inhibition of hFPPS activity, with IC 50 values of 1.108 and 1.24 μM, respectively. Docking studies further revealed that both compounds bound within the allylic binding site and near the isopentenyl diphosphate (IPP) site within the hFPPS pocket. Molecular dynamic simulations were performed on the best docking pose of the most potent compound 4a to confirm the formation of a stable complex with hFPPS. In an in vivo study conducted on ovariectomized rats, various biochemical markers including osteocalcin, estradiol, osteoprotegerin, bone mineral content, and density were negatively impacted, while levels of bone specific alkaline phosphatase, receptor activator of nuclear factor kappa-Β ligand, serum/urinary calcium, and phosphate increased. Notably, compound 4a exhibited antiresorptive properties similar to zoledronate, effectively restoring most of the perturbed biochemical estimations. These findings suggest the potential of compound 4a , a non-bisphosphonate compound, as alternative therapeutic agents for combating osteoporosis.

Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.

Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.

Synthesis and characterization of new tetrakisphosphonic acid derivatives as FPPS inhibitors and evaluation of their anti-osteoclastogenic potential for prevention of osteoporosis

Solid-state NMR, Crystallographic, and Computational Investigation of Bisphosphonates and Farnesyl Diphosphate Synthase-Bisphosphonate Complexes.

Discovery of Potent Inhibitor for Farnesyl Pyrophosphate Synthase in the Mevalonate Pathway.

Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Farnesyl Pyrophosphate Synthase As a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells

Design, Synthesis and Biological Evaluation of Pyrazolylaminoquinazoline Derivatives As Highly Potent Pan-Fibroblast Growth Factor Receptor Inhibitors.

Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.

Bisphosphonates Target Multiple Sites In Both Cis- And Trans-Prenyltransferases

Design, Synthesis and Antitumor Activity of FAK/PLK1 Dual Inhibitors with Quinazolinone as the Skeleton

Design, synthesis and antitumor activity of triphenylphosphonium-linked derivatives of quinazolinone

Synthesis and Structure-Activity Relationship of Non-Phosphorus-based Fructose-1,6-bisphosphatase Inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles.

Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Synthesis and antiosteoporosis activity of 3-phenyl-4(1H) quinolinone derivatives

Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors

Synthesis and in vitro biological evaluation of novel quinazoline derivatives.

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.

Design, synthesis and antitumor activity of novel cis-furoquinoline derivatives